Iofina plc provided a brief update to the market regarding its activities during First Quarter 2024. The Company continued to perform as expected during the Period, with Iofina Resources producing 123.7 metric tonnes ('MT') of crystalline iodine from its six IOsorb®? iodine plants in Oklahoma.

This was an increase of 15.5% from First Quarter 2023 (107.1 MT). Demand for Iofina's iodine remained strong throughout the Period and was supported by a further expansion in the customer base. The Company's sales channels remain robust, which is encouraging as it executes its production expansion plans.

Iofina's newest build, IO#10, is on track and progressing well.irt and concrete work are complete. Major components have been ordered, including the tower system which was sourced from an additional manufacturer to ensure ample supply from multiple vendors. The final steps for completion will focus on the tower installation, assembling buildings, plumbing, electricals and tying into partner's brine system, which will happen during the early summer months.

The Company continues to work on other growth projects and is in advanced dialogue with multiple partners for the next plant, IO#11. Additionally, Iofina has signed new multi-year agreements for the supply of brine water to two of Iofina Resources' current IOsorb®? plants.

The new agreed terms, with one of Iofina's existing oil & gas partners, is an important milestone in maintaining consistent iodine production at both plants, whilst enabling partners to maximise the supply of brine to these plants. The expectation remains that Iofina Resources will produce 275-295 MT of crystalline iodine during first quarter 2024 from its six existing plants (H1 2023: 241.5 MT). Iofina recognises that previous brine water supply fees for these two plants were lower than the standard market rates due to the historical nature of the contracts.

Consequently, the new contracts carry higher fees than the previous agreements. The higher fee payments, which are effective 1 January 2024, will reduce EBITDA, and the Board expects fiscal 2024 EBITDA to be in the range of $8.5-$9.0 million. On the current timetable, IO#10 should make a healthy additional contribution for the H2 period and once operating, IO#10 is expected to produce 100-150MT of crystalline iodine per annum.

The Company notes that it expects to publish its 2023 full-year financial results to the market in the coming weeks and hold its AGM in June 2024.